Navigation Links
Imagopaque®

ProductsImagopaque®
Company Amersham Health
Item Imagopaque®
Features 
Description IMAGOPAQUE is a non-ionic monomeric contrast medium for intravascular and body cavity procedures in adults and children. After a decade of clinical experience and use in over 3.5 million examinations, IMAGOPAQUE has proven to be a valuable part of the team effort in hundreds of radiology departments.Results from large multicentre monitoring trials1-3 confirm that IMAGOPAQUE is a well-tolerated, efficient contrast medium. If excellent all-round performance is what you expect from a contrast medium, team up with IMAGOPAQUE
Info Amersham Health
Customer Service: (800) 654-0118
Web site: http://www.amershamhealth-us.com/

Related medicine products :

1. Optimark®
... capabilities combined with ease of use make the O...r office or hospital-based urodynamics, the OM-5 i...leak point pressure, or urethral pressure profiles...e the OM-5 flexible enough to meet the needs of al...
... a 5 mm suture anchor that incorporates a small mi...for maximum pull-out strength in soft bone. The an...ssibility of locking the second suture after the f...e distal part of the insertion shaft indicates the...
...o use as its name implies. Third-party payers are...herapeutic procedures. For the treatment of patien...requires urodynamics. As a result, urodynamic eva...nvironment, with only complicated cases referred t...
...hute Tissue Anchor allows one step fixation of sof...scopic knotless rotator cuff repair in one simple ... an outside thread diameter of 5 mm and a small 2 ...res securely hold a thin, bioabsorbable PLLA disc ...
Medicine Products:
(Date:10/7/2008)... Surprise announcement of planned bequest comes a...PRNewswire-USNewswire/ -- Just over one year,ago, ...illion gift to the,University of Michigan, to endo... treating and preventing human disease., Today, a... --,announcing that he will bequeath an additional...
(Date:10/7/2008)... MORE THAN 100,000 PEOPLE ACROSS THE NATION HAVE... CURE(R), DALLAS, Oct. 7 /PRNewswire/ -- To ai...ll voters about the positions of presidential cand...y health care and cancer issues,the Susan G. Kome... a,series of resources available on its web site -...
(Date:10/7/2008)... Wyndstorm Corporation ( w...nues social media company, announced a key win wit...eractive marketing plan program design to promote ...Wyndstorm,s design project will ultimately help Mu...programs among employees via interactive messaging...
(Date:10/7/2008)... ,09 expansion means better access, more choices ... consumers, FORT WAYNE, Ind., Oct. 7 /PRNewswir...as reached agreement to partner with Consumers Lif...de healthcare service to consumers in,12 Indiana c...in the new network partnership is Fort Wayne,s Lut...
Breaking Medicine News(10 mins):Health News:Alfred Taubman Announces New $22M Gift to U-M 2Health News:Susan G. Komen for the Cure(R) Advocacy Alliance Educates Voters, Debate Watchers on McCain/Obama Health Care Agendas 2Health News:Susan G. Komen for the Cure(R) Advocacy Alliance Educates Voters, Debate Watchers on McCain/Obama Health Care Agendas 3Health News: 3D Social Media Application Aims to Cut Workplace Obesity : Muve, Inc., Selects Social Media Developer Wyndstorm Corporation to Design Online Promotions for Corporate Wellness Program 2Health News: 3D Social Media Application Aims to Cut Workplace Obesity : Muve, Inc., Selects Social Media Developer Wyndstorm Corporation to Design Online Promotions for Corporate Wellness Program 3Health News:Consumers Life Expands Healthcare Network in Northeast Indiana 2
...HIV/AIDS community outreach program in Delaware ha...awareness on HIV/AIDS.// Its “Do the Right Thing 4...information on HIV/AIDS prevention and treatment, ...ia the participating barbershops and beauty salons...
...Archbishop of Kingston Lawrence Burke has come dow...ons. The Jamaican government had called for // con...od if nearing its end. It is thought that there w...d on the delicate issue of abortions and naturally...
...ster Gao Qiang at the National Health Conference h...ore on providing service to the poor and needy ins...structure and expansion. He has urged the hospital... care to the rich. He has said that the Government...
...mologist has revealed that more devastating earthq...on over a period of 50 years. // They will inflict...uake in Muzaffarabad in Pakistan. Roger Bilham wh...reas of Pakistan for the past two months, said tha...
Other Medicine News:Health News:More Severe Earthquakes May Hit Kashmir In Future 2
(Date:10/6/2008)...Newswire-FirstCall/ -- Pharmasset, Inc.,(Nasdaq: ...s joining the,Company as Vice President of Investo...h will be responsible for all investor relations,f...al Officer Kurt,Leutzinger., Most recently, Dr. S...,Analyst at JPMorgan Securities, and has been an a...
(Date:10/6/2008)...ACG Annual Scientific Conference -, ORLANDO, Fla....(formerly Microbia) today announced presentation o...ing the role that cyclic guanosine,monophosphate (...studies,demonstrate that cGMP inhibits intestinal ...esia and desensitizes colonic afferent nerves in a...
(Date:10/6/2008)...ies with Durezol Dosed Prior to Surgery, TAMPA, F...nc., a,privately held ophthalmic-focused biopharma... (difluprednate ophthalmic emulsion) 0.05% is now,...d by the U.S. Food and,Drug Administration in June...cated for the treatment of inflammation and pain a...
(Date:10/6/2008)...erate to severe patients achieved endoscopic,respo...emission at Week 10,in data from a 54-week open-la...troenterology (ACG) Annual Scientific Meeting, OR...ented data from a,large, prospective study investi...CD) with a biologic compound. The data presented a...
Breaking Medicine Technology:Richard E.T. Smith, Ph.D. Joins Pharmasset as Vice President of Investor Relations and Corporate Communications 2Richard E.T. Smith, Ph.D. Joins Pharmasset as Vice President of Investor Relations and Corporate Communications 3Ironwood and Collaborators Present Preclinical Data Demonstrating That Cyclic GMP Alleviates Intestinal Pain 2Ironwood and Collaborators Present Preclinical Data Demonstrating That Cyclic GMP Alleviates Intestinal Pain 3Video: Sirion Therapeutics Launches Durezol for Postoperative Ocular Inflammation and Pain 2Video: Sirion Therapeutics Launches Durezol for Postoperative Ocular Inflammation and Pain 3Video: Sirion Therapeutics Launches Durezol for Postoperative Ocular Inflammation and Pain 4Video: Sirion Therapeutics Launches Durezol for Postoperative Ocular Inflammation and Pain 5CIMZIA(R) (certolizumab pegol) Reduces Intestinal Lesions and Induces Endoscopic Improvement in Crohn's Patients 2CIMZIA(R) (certolizumab pegol) Reduces Intestinal Lesions and Induces Endoscopic Improvement in Crohn's Patients 3CIMZIA(R) (certolizumab pegol) Reduces Intestinal Lesions and Induces Endoscopic Improvement in Crohn's Patients 4CIMZIA(R) (certolizumab pegol) Reduces Intestinal Lesions and Induces Endoscopic Improvement in Crohn's Patients 5CIMZIA(R) (certolizumab pegol) Reduces Intestinal Lesions and Induces Endoscopic Improvement in Crohn's Patients 6CIMZIA(R) (certolizumab pegol) Reduces Intestinal Lesions and Induces Endoscopic Improvement in Crohn's Patients 7Test Detects Sensitivity to HIV Drug 11202 1Test Detects Sensitivity to HIV Drug 11202 2Gene found to play a suppressor role in skin cancer development 11198 1Gene found to play a suppressor role in skin cancer development 11198 2Elephant Ensemble Theater Brings New Production to Bronx Hospitals 11194 1Gerontology conferences highlights to include talks on student social networking 11190 1Gerontology conferences highlights to include talks on student social networking 11190 2
...ts and physicians should find these data reassurin...all/ --,GlaxoSmithKline said today that findings f...valuated for Cardiac Outcomes and,Regulation of gl...designed specifically to determine cardiovascular ...iabetes, adds further evidence to,the overall card...
...K--(BUSINESS WIRE)--Jun 5, 2007 - ERBITUX (cetuxim...argeting the epidermal,growth factor receptor (EGF... Incorporated, was the focus of nine oral and 46,p... Annual Meeting,of the American Society of Clinica...ntations showcased the extensive,clinical developm...
Other Medicine Technology:Interim Data From RECORD Study Show No Significant Difference,Between Avandia and Standard Therapy in Risk of Cardiovascular,Hospitalization or Death 2Interim Data From RECORD Study Show No Significant Difference,Between Avandia and Standard Therapy in Risk of Cardiovascular,Hospitalization or Death 3Interim Data From RECORD Study Show No Significant Difference,Between Avandia and Standard Therapy in Risk of Cardiovascular,Hospitalization or Death 4Interim Data From RECORD Study Show No Significant Difference,Between Avandia and Standard Therapy in Risk of Cardiovascular,Hospitalization or Death 5Extensive Clinical Data on Erbitux Presented at the 2007 ASCO,Annual Meeting 2Extensive Clinical Data on Erbitux Presented at the 2007 ASCO,Annual Meeting 3Extensive Clinical Data on Erbitux Presented at the 2007 ASCO,Annual Meeting 4Extensive Clinical Data on Erbitux Presented at the 2007 ASCO,Annual Meeting 5Extensive Clinical Data on Erbitux Presented at the 2007 ASCO,Annual Meeting 6Extensive Clinical Data on Erbitux Presented at the 2007 ASCO,Annual Meeting 7Extensive Clinical Data on Erbitux Presented at the 2007 ASCO,Annual Meeting 8Extensive Clinical Data on Erbitux Presented at the 2007 ASCO,Annual Meeting 9Extensive Clinical Data on Erbitux Presented at the 2007 ASCO,Annual Meeting 10